サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1467797

メタボロミクス市場レポート：製品、適応症、用途、地域別、2024～2032年

Metabolomics Market Report by Product, Indication, Application, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 138 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
メタボロミクス市場レポート：製品、適応症、用途、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のメタボロミクス市場規模は2023年に27億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに65億米ドルに達し、2024～2032年の間に10.1%の成長率（CAGR）を示すと予測しています。個別化医療に対する需要の高まり、慢性疾患の有病率の上昇、製薬とバイオテクノロジー研究の拡大、高度なバイオマーカーと創薬ソリューションの必要性が、市場を推進する主要要因の一部です。

メタボロミクスは、生命科学の領域における最先端のセグメントで、生体システム内の代謝物と呼ばれる低分子の包括的な研究に焦点を当てています。これらの代謝物には、糖、アミノ酸、脂質、その他の細胞内化合物などの物質が含まれ、様々な生物学的プロセスにおいて重要な役割を果たしています。メタボロミクスは、質量分析や核磁気共鳴分光法などの高度な分析技術を駆使して、これらの代謝物を同定・定量します。そうすることで、生物の代謝状態に関する洞察を提供し、健康、病気、薬剤反応、環境の影響に関する貴重な情報を記載しています。

メタボロミクスの世界市場は、個別化医療と医療においてメタボロミクスが果たす重要な役割が認識されつつあることを主要要因として、力強い成長を遂げています。これに伴い、メタボロミクスは個人固有の代謝プロファイルを理解するための強力なツールを提供し、より正確な診断、治療法の選択、オーダーメイドの医療プランを可能にすることで、市場の成長を強化しています。さらに、慢性疾患の有病率の増加、疾患の早期発見と予防の必要性がメタボロミクス技術への需要を押し上げ、市場拡大の明るい展望を生み出しています。これに加えて、病気に関連する代謝バイオマーカーを同定するためにこれらの技術が広く採用され、早期介入やモニタリングが容易になったことも、市場の成長に寄与しています。さらに、製薬・バイオテクノロジー研究の拡大と創薬開発の推進が、薬剤メカニズムの解明、薬効予測、安全性評価のためのメタボロミクス需要を促進しています。

メタボロミクス市場の動向と促進要因：

個別化医療の進展

メタボロミクス市場の最も大きな促進要因の1つは、個別化医療の重要性の高まりです。医療は画一的なアプローチから脱却しつつあり、メタボロミクスは個々の患者に合わせた治療を行う上で極めて重要な役割を果たしています。この変化は、遺伝的変異だけでは個人の健康状態を完全に把握できないという認識によるところが大きいです。メタボロミクスは、個人の代謝プロファイルのダイナミックな変化を捉えることで、ゲノミクスを補完し、疾患、薬剤、環境要因に対する独自の反応を反映します。その結果、メタボロミクスによって医療プロバイダーは、より正確な診断、個別化された治療法の選択、治療効果のモニタリングを行うことができるようになります。例えば、がん治療では、メタボロミクスによって患者の腫瘍で代謝異常が起きている特定の代謝経路を特定できるため、腫瘍医が最も効果的な治療法を選択するのに役立ちます。

慢性疾患の増加

糖尿病、心血管疾患、肥満などの慢性疾患の世界の増加も、メタボロミクス市場の重要な促進要因です。メタボロミクスは、疾患の早期発見、リスク評価、モニタリングのための強力なツールとなります。メタボロームバイオマーカーを分析することで、研究者や臨床医は、疾患の臨床的発現に先行する可能性のある個人の代謝プロファイルの微妙な変化を特定することができます。この早期警告システムは、予防措置の実施、疾病発症の初期段階での治療開始、疾病進行の追跡にとって極めて重要です。さらに、生活習慣に関連する要因が慢性疾患の増加に寄与していることから、メタボロミクスは、食事の選択、身体活動、環境暴露が個人の代謝の健康にどのような影響を与えるかを明らかにすることができます。

製薬とバイオテクノロジー研究

製薬とバイオテクノロジーセグメントでは、創薬と薬剤開発プロセスを強化するためにメタボロミクスへの依存度が高まっています。メタボロミクスは、薬剤のメカニズム、有効性、安全性に関する洞察を提供し、薬剤開発のパイプラインを加速します。研究者はメタボロミクスを利用して、創薬対象の同定と検証、潜在的な薬剤候補の代謝効果の評価、薬剤動態と毒性の予測を行っています。このような情報は、医薬品開発プロセスを合理化し、コストのかかる後期段階の失敗を減らし、革新的な治療法を市場に投入する可能性を高めるのに役立ちます。さらに、メタボロミクスは、薬剤相互作用の理解、投与レジメンの最適化、臨床試験中の患者反応のモニタリングに不可欠であり、医薬品開発の全体的な効率と成功に貢献します。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界のメタボロミクス市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • メタボロミクス機器
  • メタボロミクス・バイオインフォマティクスツールとサービス

第7章 市場内訳：適応症別

  • がん領域
  • 心血管疾患
  • 神経疾患
  • 先天性代謝異常
  • その他

第8章 市場内訳：用途別

  • バイオマーカー・創薬
  • トキシコロジー
  • ニュートリゲノミクス
  • 個別化医療
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Agilent Technologies Inc.
    • Biocrates Life Sciences AG
    • Bio-Rad Laboratories Inc.
    • Bruker Corporation
    • Danaher Corporation
    • Human Metabolome Technologies Inc.
    • Metabolon Inc.
    • Shimadzu Corporation
    • Thermo Fisher Scientific Inc.
    • Waters Corporation
図表

List of Figures

  • Figure 1: Global: Metabolomics Market: Major Drivers and Challenges
  • Figure 2: Global: Metabolomics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Metabolomics Market: Breakup by Product (in %), 2023
  • Figure 4: Global: Metabolomics Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Metabolomics Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Metabolomics Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Metabolomics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Metabolomics (Metabolomics Instruments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Metabolomics (Metabolomics Instruments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Metabolomics (Metabolomics Bioinformatics Tools and Services) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Metabolomics (Metabolomics Bioinformatics Tools and Services) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Metabolomics (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Metabolomics (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Metabolomics (Cardiovascular Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Metabolomics (Cardiovascular Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Metabolomics (Neurological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Metabolomics (Neurological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Metabolomics (Inborn Errors of Metabolism) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Metabolomics (Inborn Errors of Metabolism) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Metabolomics (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Metabolomics (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Metabolomics (Biomarker and Drug Discovery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Metabolomics (Biomarker and Drug Discovery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Metabolomics (Toxicology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Metabolomics (Toxicology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Metabolomics (Nutrigenomics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Metabolomics (Nutrigenomics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Metabolomics (Personalized Medicine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Metabolomics (Personalized Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Metabolomics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Metabolomics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia Pacific: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia Pacific: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Global: Metabolomics Industry: SWOT Analysis
  • Figure 81: Global: Metabolomics Industry: Value Chain Analysis
  • Figure 82: Global: Metabolomics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Metabolomics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Metabolomics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Metabolomics Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 4: Global: Metabolomics Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Metabolomics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Metabolomics Market: Competitive Structure
  • Table 7: Global: Metabolomics Market: Key Players
目次
Product Code: SR112024A2024

The global metabolomics market size reached US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.5 Billion by 2032, exhibiting a growth rate (CAGR) of 10.1% during 2024-2032. The growing demand for personalized medicine, rising prevalence of chronic diseases, expanding pharmaceutical and biotechnology research, and the need for advanced biomarker and drug discovery solutions are some of the major factors propelling the market.

Metabolomics is a cutting-edge field in the realm of life sciences that focuses on the comprehensive study of small molecules called metabolites within biological systems. These metabolites include substances such as sugars, amino acids, lipids, and other cellular compounds, and they play crucial roles in various biological processes. Metabolomics employ advanced analytical techniques, such as mass spectrometry and nuclear magnetic resonance spectroscopy, to identify and quantify these metabolites. By doing so, it offers insights into an organism's metabolic state, providing valuable information about health, disease, drug responses, and environmental influences.

The global metabolomics market is experiencing robust growth, primarily driven by the growing recognition of the pivotal role that this compound plays in personalized medicine and healthcare. In line with this, metabolomics provides a powerful tool for understanding an individual's unique metabolic profile, enabling more precise diagnosis, treatment selection, and tailored healthcare plans, thereby strengthening the market growth. Moreover, the increasing prevalence of chronic diseases and the need for early disease detection and prevention are boosting demand for metabolomics technologies, creating a positive outlook for market expansion. In addition to this, the widespread adoption of these technologies to identify metabolic biomarkers associated with diseases, facilitating early intervention and monitoring, is contributing to the market's growth. Furthermore, the expansion of pharmaceutical and biotechnology research, coupled with the drive for drug discovery and development, is fueling demand for metabolomics to elucidate drug mechanisms, predict drug efficacy, and assess safety.

Metabolomics Market Trends/Drivers:

Advancements in personalized medicine

One of the foremost drivers of the metabolomics market is the increasing importance of personalized medicine. Healthcare is moving away from a one-size-fits-all approach, and metabolomics plays a pivotal role in tailoring treatments to individual patients. This shift is largely due to the recognition that genetic variations alone do not provide a complete understanding of an individual's health. Metabolomics complements genomics by capturing dynamic changes in an individual's metabolic profile, reflecting their unique response to diseases, drugs, and environmental factors. As a result, metabolomics enables healthcare providers to make more precise diagnoses, select personalized treatment options, and monitor therapeutic responses. For example, in cancer treatment, metabolomics can identify specific metabolic pathways that are dysregulated in a patient's tumor, helping oncologists choose the most effective therapies.

Rising prevalence of chronic diseases

The escalating global burden of chronic diseases including diabetes, cardiovascular disorders, and obesity is another significant driver of the metabolomics market. Metabolomics provides a powerful tool for early disease detection, risk assessment, and monitoring. By analyzing metabolic biomarkers, researchers and clinicians can identify subtle changes in an individual's metabolic profile that may precede the clinical manifestation of a disease. This early warning system is crucial for implementing preventive measures, initiating treatments at the earliest stages of disease development, and tracking disease progression. Additionally, as lifestyle-related factors contribute to the rise in chronic diseases, metabolomics can shed light on how dietary choices, physical activity, and environmental exposures impact an individual's metabolic health.

Pharmaceutical and biotechnology research

The pharmaceutical and biotechnology sectors are increasingly relying on metabolomics to enhance drug discovery and development processes. Metabolomics offers insights into drug mechanisms, efficacy, and safety, thereby accelerating the drug development pipeline. Researchers use metabolomics to identify and validate drug targets, assess the metabolic effects of potential drug candidates, and predict their pharmacokinetics and toxicity. This information helps streamline the drug development process, reduce costly late-stage failures, and improve the chances of bringing innovative therapies to market. Moreover, metabolomics is crucial for understanding drug interactions, optimizing dosing regimens, and monitoring patient responses during clinical trials, contributing to the overall efficiency and success of drug development efforts.

Metabolomics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global metabolomics market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, indication, and application.

Breakup by Product:

Metabolomics Instruments

Metabolomics Bioinformatics Tools and Services

Metabolomics bioinformatics tools and services dominate the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes metabolomics instruments and metabolomics bioinformatics tools and services. According to the report, metabolomics bioinformatics tools and services represented the largest segment.

The demand for metabolomics bioinformatic tools and services is mainly propelled by the complexity and volume of data generated in metabolomics research. Metabolomics experiments produce vast datasets with intricate molecular information, making data analysis and interpretation a significant challenge. Besides this, metabolomics bioinformatic tools and services are essential for processing, managing, and extracting meaningful insights from this wealth of data. Furthermore, the integration of multi-omics data, including genomics, proteomics, and metabolomics, is becoming increasingly crucial to gain a holistic understanding of biological systems. To harness the full potential of metabolomics data, researchers require sophisticated software solutions and expert services that can handle data preprocessing, statistical analysis, pathway mapping, and biomarker identification. As metabolomics continues to expand its applications in diverse fields, the demand for bioinformatic tools and services is set to rise, enabling researchers to unlock the valuable information hidden within their datasets.

Breakup by Indication:

Cancer

Cardiovascular Disorders

Neurological Disorders

Inborn Errors of Metabolism

Others

Cancer holds the largest share in the market

A detailed breakup and analysis of the market based on the indication has also been provided in the report. This includes cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. According to the report, cancer accounted for the largest market share.

The urgent need for more precise and early detection methods, as well as personalized treatment strategies in cancer research and diagnostics is strengthening the demand for metabolomics. They offer a unique advantage in cancer studies by providing a real-time snapshot of an individual's metabolic profile, allowing for the identification of specific metabolic alterations associated with different types and stages of cancer. These metabolic signatures can serve as potential biomarkers for early cancer detection, enabling clinicians to detect malignancies at a more treatable stage. Furthermore, as cancer treatment often leads to metabolic changes and varying responses in patients, metabolomics can assist in tailoring therapeutic approaches by monitoring how a patient's metabolism reacts to specific cancer treatments. This personalized approach has the potential to enhance treatment outcomes and minimize adverse effects, driving the demand for metabolomics applications in the field of oncology.

Breakup by Application:

Biomarker and Drug Discovery

Toxicology

Nutrigenomics

Personalized Medicine

Others

Biomarker and drug discovery dominates the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes biomarker and drug discovery, toxicology, nutrigenomics, personalized medicine, and others. According to the report, biomarker and drug discovery represented the largest segment.

The burgeoning demand for metabolomics in biomarker and drug discovery applications is driven by its unparalleled ability to unveil novel biomarkers and therapeutic targets. Metabolomics allows researchers to delve deep into an organism's biochemical landscape, identifying subtle metabolic changes associated with diseases and drug responses that may go unnoticed by other omics techniques. This capability is invaluable in biomarker discovery, where metabolomics can pinpoint specific metabolites indicative of disease presence, progression, or treatment efficacy. Additionally, in drug discovery, metabolomics plays a pivotal role in elucidating drug mechanisms and assessing potential drug candidates' safety profiles by uncovering their metabolic impact. By providing a comprehensive view of the intricate interactions within biological systems, metabolomics accelerates the identification of promising drug targets, expedites the development of new therapies, and minimizes the risk of late-stage drug failures, thereby fueling the demand for metabolomics in these critical areas of research.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest metabolomics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a thriving biopharmaceutical and healthcare industry, characterized by substantial investments in research and development (R&D). This robust ecosystem fuels the demand for metabolomics technologies in drug discovery and personalized medicine applications, as pharmaceutical companies seek innovative solutions to expedite drug development and enhance patient care. Concurrent with this, the region's healthcare infrastructure places a strong emphasis on precision medicine, with government initiatives and healthcare institutions increasingly recognizing the potential of metabolomics for tailoring treatments and improving patient outcomes. Furthermore, collaborations between academic research institutions and industry players in North America have paved the way for cutting-edge metabolomics research, further propelling the market's growth. These factors, combined with a favorable regulatory environment, position North America as a key hub for metabolomics innovation and adoption, driving the market forward.

Competitive Landscape:

The competitive landscape of the global metabolomics market is dynamic and characterized by intense competition among both established players and emerging companies. Leading companies dominate the market with their comprehensive portfolios of metabolomics instruments, software, and services. These industry giants focus on continuous innovation, strategic partnerships, and acquisitions to expand their market presence and offer integrated solutions to customers. Additionally, academic institutions and research organizations contribute significantly to the market by developing cutting-edge metabolomics technologies and methodologies and fostering collaborations with industry stakeholders. Emerging startups, specializing in niche metabolomics applications, are also gaining traction by introducing innovative tools and services, enhancing competition and driving market growth. Furthermore, the market's global nature makes it highly competitive on a regional basis, with regional players catering to specific geographical preferences and regulations.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Agilent Technologies Inc.

Biocrates Life Sciences AG

Bio-Rad Laboratories Inc.

Bruker Corporation

Danaher Corporation

Human Metabolome Technologies Inc.

Metabolon Inc.

Shimadzu Corporation

Thermo Fisher Scientific Inc.

Waters Corporation

Recent Developments:

In June 2021, Bruker Corporation unveiled the FluoroTypeSARS-CoV-2 Varied Q assay, a quantitative Liquid Array mid-plexPCR panel that identifies the presence of the virus and detects key mutations, allowing laboratories and hospitals to routinely distinguish between major viral variants in positive samples.

In June 2021, Thermo Fischer Scientific launched the Orbitrap IQ-X Tribrid mass spectrometer, the latest in their Next-Generation MS-Based Solutions lineup, designed specifically to elucidate intricate chemical structures for precise compound identification.

Key Questions Answered in This Report:

  • How has the global metabolomics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global metabolomics market?
  • What is the impact of each driver, restraint, and opportunity on the global metabolomics market?
  • What are the key regional markets?
  • Which countries represent the most attractive metabolomics market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the metabolomics market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the metabolomics market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the metabolomics market?
  • What is the competitive structure of the global metabolomics market?
  • Who are the key players/companies in the global metabolomics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Metabolomics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Metabolomics Instruments
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Metabolomics Bioinformatics Tools and Services
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiovascular Disorders
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurological Disorders
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Inborn Errors of Metabolism
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Biomarker and Drug Discovery
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Toxicology
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Nutrigenomics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Personalized Medicine
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Agilent Technologies Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Biocrates Life Sciences AG
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Bio-Rad Laboratories Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bruker Corporation
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
    • 13.3.5 Danaher Corporation
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Human Metabolome Technologies Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
    • 13.3.7 Metabolon Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 Shimadzu Corporation
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Thermo Fisher Scientific Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Waters Corporation
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis